Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.

@article{Wang2005ChronicIT,
  title={Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.},
  author={Julie A Wang and Joseph M Wiley and Ruth E Luddy and Jay N. Greenberg and Michael A Feuerstein and James B Bussel},
  journal={The Journal of pediatrics},
  year={2005},
  volume={146 2},
  pages={217-21}
}
OBJECTIVES This study examined the efficacy and safety of rituximab in children with chronic immune thrombocytopenic purpura. STUDY DESIGN Twenty-four patients, 2 to 19 years of age, with platelet counts <30,000/mcL (microliter 2), received 375 mg/m 2 rituximab in 4 weekly doses. Platelet response was characterized as complete (CR) if a count >150,000/mcL was achieved; partial (PR) if 50,000 to 150,000/mcL; minimal (MR) if the count increased by >20,000/mcL to a peak count >30,000/mcL but <50… CONTINUE READING
31 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…